-transparent.png){kind=logo}
A human stomach-adenocarcinoma cell line (MKN-45) was selected for resistance to Adriamycin by stepwise exposure to increasing concentrations of this agent. The resulting cell line (MKN/ADR) exhibited a high level of cross-resistance to topoisomerase II (topo II)-targeted drugs such as Adriamycin, mitoxantrone, and etoposide but showed no cross-resistance to other chemotherapeutic agents such as cisplatin, carboplatin, 5-fluorouracil, or mitomycin-C. P-glycoprotein encoded by the mdr-1 gene was not overexpressed in the MKN/ADR cell line. The doubling time of the MKN/ADR cell line (2.1 days) increased only slightly as compared with that of the MKN cell line (1.7 days). The patterns of cross-resistance to various chemotherapeutic agents led us to examine the cellular contents of topo II in both the drug-sensitive and the drug-resistant cells. Extractable topo II enzyme activity was 3-fold lower in MKN/ADR cells as compared with the parental MKN cells. Levels of topoisomerase I (topo I) catalytic activity were similar in both wild-type MKN and drug-resistant MKN/ADR cells. Southern-blot analysis of genomic DNA probed with topo IIalpha or IIbeta showed no sign of either gene rearrangement or hypermethylation. Northern-blot analysis revealed that both topo IIalpha and topo IIbeta mRNA transcripts were essentially identical in the MKN and MKN/ADR cells. In contrast, Western-blot analysis revealed an approximately 20-fold lower level of topo IIalpha in drug-resistant cells as compared with drug-sensitive cells, whereas topo IIbeta levels were similar in both lines. Moreover, the amount of in vivo topo IIalpha-DNA covalent complexes formed in the presence of etoposide was also approximately 20-fold lower in drug-resistant cells. No mutation was detected in the promoter region of the topo IIalpha gene in resistant cells as compared with sensitive cells. Thus, low levels of topo IIalpha polypeptide cannot be ascribed to changes in the mRNA levels. Collectively, the data suggest that a quantitative reduction in topo IIalpha may contribute to the resistance of MKN cells to Adriamycin and other topo II-targeted drugs.
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1990,
Cancer research,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1991,
Anticancer research,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
August 1993,
International journal of oncology,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1995,
British journal of cancer,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1990,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
April 2002,
Molecules and cells,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1994,
Cancer chemotherapy and pharmacology,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
September 1994,
Molecular pharmacology,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
January 1994,
Biochemical and biophysical research communications,
Y S Son, and
J M Suh, and
S H Ahn, and
J C Kim, and
J Y Yi, and
K C Hur, and
W S Hong, and
M T Muller, and
I K Chung
December 1998,
Cancer research,
